COVID-19 Impact on Global Personalized Medicine and Epigenomics Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-personalized-medicine-n-epigenomics-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global Personalized Medicine and Epigenomics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Personalized Medicine and Epigenomics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Abbott Laboratories
- Affymetrix
- Agilent Technologies
- Astellas Pharmaceuticals
- BAYER AG
- Bio Vision
- Celgene Corp.
- Emd Millipore
- Epigenomics AG
- Epigentex
- Envivo Pharmaceuticals (Forum Pharmaceutricals)
- Gilead Sciences
- Glaxosmithkline
- Illumina Inc.
- Johnson & Johnson
- Karus Therapeutics Limited
- Laboratory Corp. Of America Holdings
- LES Laboratoires Servier
- Merck
- Naturewise Biotech & Medicals Corp.
- Novartis Pharma AG
- Oncolys Biopharma Inc.
- Orchid Chemicals & Pharmaceuticals Limited
- Progen Pharmaceuticals Limited
- Quest Diagnostics
- Roche Holding AG
- Rubicon Genomics
- Takeda Pharmaceutical Company Limited
- Reagents
- Kits
- Instruments
- Enzymes
- Services
- Oncology
- Non-Oncology
- Cancer Drug Technology
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Personalized Medicine and Epigenomics status, future forecast, growth opportunity, key market and key players.
- To present the Personalized Medicine and Epigenomics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
1.4 Market Analysis by Type
1.4.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Reagents
1.4.3 Kits
1.4.4 Instruments
1.4.5 Enzymes
1.4.6 Services
1.5 Market by Application
1.5.1 Global Personalized Medicine and Epigenomics Market Share by Application: 2020 VS 2026
1.5.2 Oncology
1.5.3 Non-Oncology
1.5.4 Cancer Drug Technology
1.6 Coronavirus Disease 2019 (Covid-19): Personalized Medicine and Epigenomics Industry Impact
1.6.1 How the Covid-19 is Affecting the Personalized Medicine and Epigenomics Industry
1.6.1.1 Personalized Medicine and Epigenomics Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Personalized Medicine and Epigenomics Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Personalized Medicine and Epigenomics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Personalized Medicine and Epigenomics Market Perspective (2015-2026)
2.2 Personalized Medicine and Epigenomics Growth Trends by Regions
2.2.1 Personalized Medicine and Epigenomics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Personalized Medicine and Epigenomics Historic Market Share by Regions (2015-2020)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Personalized Medicine and Epigenomics Market Growth Strategy
2.3.6 Primary Interviews with Key Personalized Medicine and Epigenomics Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Personalized Medicine and Epigenomics Players by Market Size
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2015-2020)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2015-2020)
3.1.3 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.2.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2019
3.3 Personalized Medicine and Epigenomics Key Players Head office and Area Served
3.4 Key Players Personalized Medicine and Epigenomics Product Solution and Service
3.5 Date of Enter into Personalized Medicine and Epigenomics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2015-2020)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2021-2026)
5 PERSONALIZED MEDICINE AND EPIGENOMICS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Personalized Medicine and Epigenomics Market Size (2015-2020)
6.2 Personalized Medicine and Epigenomics Key Players in North America (2019-2020)
6.3 North America Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
6.4 North America Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Personalized Medicine and Epigenomics Market Size (2015-2020)
7.2 Personalized Medicine and Epigenomics Key Players in Europe (2019-2020)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
7.4 Europe Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
8 CHINA
8.1 China Personalized Medicine and Epigenomics Market Size (2015-2020)
8.2 Personalized Medicine and Epigenomics Key Players in China (2019-2020)
8.3 China Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
8.4 China Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Personalized Medicine and Epigenomics Market Size (2015-2020)
9.2 Personalized Medicine and Epigenomics Key Players in Japan (2019-2020)
9.3 Japan Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
9.4 Japan Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Personalized Medicine and Epigenomics Market Size (2015-2020)
10.2 Personalized Medicine and Epigenomics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
10.4 Southeast Asia Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
11 INDIA
11.1 India Personalized Medicine and Epigenomics Market Size (2015-2020)
11.2 Personalized Medicine and Epigenomics Key Players in India (2019-2020)
11.3 India Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
11.4 India Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Personalized Medicine and Epigenomics Market Size (2015-2020)
12.2 Personalized Medicine and Epigenomics Key Players in Central & South America (2019-2020)
12.3 Central & South America Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
12.4 Central & South America Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Abbott Laboratories
13.1.1 Abbott Laboratories Company Details
13.1.2 Abbott Laboratories Business Overview and Its Total Revenue
13.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
13.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2015-2020))
13.1.5 Abbott Laboratories Recent Development
13.2 Affymetrix
13.2.1 Affymetrix Company Details
13.2.2 Affymetrix Business Overview and Its Total Revenue
13.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
13.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.2.5 Affymetrix Recent Development
13.3 Agilent Technologies
13.3.1 Agilent Technologies Company Details
13.3.2 Agilent Technologies Business Overview and Its Total Revenue
13.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
13.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.3.5 Agilent Technologies Recent Development
13.4 Astellas Pharmaceuticals
13.4.1 Astellas Pharmaceuticals Company Details
13.4.2 Astellas Pharmaceuticals Business Overview and Its Total Revenue
13.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
13.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.4.5 Astellas Pharmaceuticals Recent Development
13.5 BAYER AG
13.5.1 BAYER AG Company Details
13.5.2 BAYER AG Business Overview and Its Total Revenue
13.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
13.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.5.5 BAYER AG Recent Development
13.6 Bio Vision
13.6.1 Bio Vision Company Details
13.6.2 Bio Vision Business Overview and Its Total Revenue
13.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
13.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.6.5 Bio Vision Recent Development
13.7 Celgene Corp.
13.7.1 Celgene Corp. Company Details
13.7.2 Celgene Corp. Business Overview and Its Total Revenue
13.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
13.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.7.5 Celgene Corp. Recent Development
13.8 Emd Millipore
13.8.1 Emd Millipore Company Details
13.8.2 Emd Millipore Business Overview and Its Total Revenue
13.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
13.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.8.5 Emd Millipore Recent Development
13.9 Epigenomics AG
13.9.1 Epigenomics AG Company Details
13.9.2 Epigenomics AG Business Overview and Its Total Revenue
13.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
13.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.9.5 Epigenomics AG Recent Development
13.10 Epigentex
13.10.1 Epigentex Company Details
13.10.2 Epigentex Business Overview and Its Total Revenue
13.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
13.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.10.5 Epigentex Recent Development
13.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
10.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
10.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview and Its Total Revenue
10.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
10.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
13.12 Gilead Sciences
10.12.1 Gilead Sciences Company Details
10.12.2 Gilead Sciences Business Overview and Its Total Revenue
10.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
10.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.12.5 Gilead Sciences Recent Development
13.13 Glaxosmithkline
10.13.1 Glaxosmithkline Company Details
10.13.2 Glaxosmithkline Business Overview and Its Total Revenue
10.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
10.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.13.5 Glaxosmithkline Recent Development
13.14 Illumina Inc.
10.14.1 Illumina Inc. Company Details
10.14.2 Illumina Inc. Business Overview and Its Total Revenue
10.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
10.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.14.5 Illumina Inc. Recent Development
13.15 Johnson & Johnson
10.15.1 Johnson & Johnson Company Details
10.15.2 Johnson & Johnson Business Overview and Its Total Revenue
10.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
10.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.15.5 Johnson & Johnson Recent Development
13.16 Karus Therapeutics Limited
10.16.1 Karus Therapeutics Limited Company Details
10.16.2 Karus Therapeutics Limited Business Overview and Its Total Revenue
10.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
10.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.16.5 Karus Therapeutics Limited Recent Development
13.17 Laboratory Corp. Of America Holdings
10.17.1 Laboratory Corp. Of America Holdings Company Details
10.17.2 Laboratory Corp. Of America Holdings Business Overview and Its Total Revenue
10.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
10.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.17.5 Laboratory Corp. Of America Holdings Recent Development
13.18 LES Laboratoires Servier
10.18.1 LES Laboratoires Servier Company Details
10.18.2 LES Laboratoires Servier Business Overview and Its Total Revenue
10.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
10.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.18.5 LES Laboratoires Servier Recent Development
13.19 Merck
10.19.1 Merck Company Details
10.19.2 Merck Business Overview and Its Total Revenue
10.19.3 Merck Personalized Medicine and Epigenomics Introduction
10.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.19.5 Merck Recent Development
13.20 Naturewise Biotech & Medicals Corp.
10.20.1 Naturewise Biotech & Medicals Corp. Company Details
10.20.2 Naturewise Biotech & Medicals Corp. Business Overview and Its Total Revenue
10.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
10.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.20.5 Naturewise Biotech & Medicals Corp. Recent Development
13.21 Novartis Pharma AG
10.21.1 Novartis Pharma AG Company Details
10.21.2 Novartis Pharma AG Business Overview and Its Total Revenue
10.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
10.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.21.5 Novartis Pharma AG Recent Development
13.22 Oncolys Biopharma Inc.
10.22.1 Oncolys Biopharma Inc. Company Details
10.22.2 Oncolys Biopharma Inc. Business Overview and Its Total Revenue
10.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
10.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.22.5 Oncolys Biopharma Inc. Recent Development
13.23 Orchid Chemicals & Pharmaceuticals Limited
10.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
10.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview and Its Total Revenue
10.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
10.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
13.24 Progen Pharmaceuticals Limited
10.24.1 Progen Pharmaceuticals Limited Company Details
10.24.2 Progen Pharmaceuticals Limited Business Overview and Its Total Revenue
10.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
10.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.24.5 Progen Pharmaceuticals Limited Recent Development
13.25 Quest Diagnostics
10.25.1 Quest Diagnostics Company Details
10.25.2 Quest Diagnostics Business Overview and Its Total Revenue
10.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
10.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.25.5 Quest Diagnostics Recent Development
13.26 Roche Holding AG
10.26.1 Roche Holding AG Company Details
10.26.2 Roche Holding AG Business Overview and Its Total Revenue
10.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
10.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.26.5 Roche Holding AG Recent Development
13.27 Rubicon Genomics
10.27.1 Rubicon Genomics Company Details
10.27.2 Rubicon Genomics Business Overview and Its Total Revenue
10.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
10.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.27.5 Rubicon Genomics Recent Development
13.28 Takeda Pharmaceutical Company Limited
10.28.1 Takeda Pharmaceutical Company Limited Company Details
10.28.2 Takeda Pharmaceutical Company Limited Business Overview and Its Total Revenue
10.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
10.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.28.5 Takeda Pharmaceutical Company Limited Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
1.4 Market Analysis by Type
1.4.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Reagents
1.4.3 Kits
1.4.4 Instruments
1.4.5 Enzymes
1.4.6 Services
1.5 Market by Application
1.5.1 Global Personalized Medicine and Epigenomics Market Share by Application: 2020 VS 2026
1.5.2 Oncology
1.5.3 Non-Oncology
1.5.4 Cancer Drug Technology
1.6 Coronavirus Disease 2019 (Covid-19): Personalized Medicine and Epigenomics Industry Impact
1.6.1 How the Covid-19 is Affecting the Personalized Medicine and Epigenomics Industry
1.6.1.1 Personalized Medicine and Epigenomics Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Personalized Medicine and Epigenomics Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Personalized Medicine and Epigenomics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Personalized Medicine and Epigenomics Market Perspective (2015-2026)
2.2 Personalized Medicine and Epigenomics Growth Trends by Regions
2.2.1 Personalized Medicine and Epigenomics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Personalized Medicine and Epigenomics Historic Market Share by Regions (2015-2020)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Personalized Medicine and Epigenomics Market Growth Strategy
2.3.6 Primary Interviews with Key Personalized Medicine and Epigenomics Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Personalized Medicine and Epigenomics Players by Market Size
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2015-2020)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2015-2020)
3.1.3 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.2.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2019
3.3 Personalized Medicine and Epigenomics Key Players Head office and Area Served
3.4 Key Players Personalized Medicine and Epigenomics Product Solution and Service
3.5 Date of Enter into Personalized Medicine and Epigenomics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2015-2020)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2021-2026)
5 PERSONALIZED MEDICINE AND EPIGENOMICS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Personalized Medicine and Epigenomics Market Size (2015-2020)
6.2 Personalized Medicine and Epigenomics Key Players in North America (2019-2020)
6.3 North America Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
6.4 North America Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Personalized Medicine and Epigenomics Market Size (2015-2020)
7.2 Personalized Medicine and Epigenomics Key Players in Europe (2019-2020)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
7.4 Europe Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
8 CHINA
8.1 China Personalized Medicine and Epigenomics Market Size (2015-2020)
8.2 Personalized Medicine and Epigenomics Key Players in China (2019-2020)
8.3 China Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
8.4 China Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Personalized Medicine and Epigenomics Market Size (2015-2020)
9.2 Personalized Medicine and Epigenomics Key Players in Japan (2019-2020)
9.3 Japan Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
9.4 Japan Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Personalized Medicine and Epigenomics Market Size (2015-2020)
10.2 Personalized Medicine and Epigenomics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
10.4 Southeast Asia Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
11 INDIA
11.1 India Personalized Medicine and Epigenomics Market Size (2015-2020)
11.2 Personalized Medicine and Epigenomics Key Players in India (2019-2020)
11.3 India Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
11.4 India Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Personalized Medicine and Epigenomics Market Size (2015-2020)
12.2 Personalized Medicine and Epigenomics Key Players in Central & South America (2019-2020)
12.3 Central & South America Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
12.4 Central & South America Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Abbott Laboratories
13.1.1 Abbott Laboratories Company Details
13.1.2 Abbott Laboratories Business Overview and Its Total Revenue
13.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
13.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2015-2020))
13.1.5 Abbott Laboratories Recent Development
13.2 Affymetrix
13.2.1 Affymetrix Company Details
13.2.2 Affymetrix Business Overview and Its Total Revenue
13.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
13.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.2.5 Affymetrix Recent Development
13.3 Agilent Technologies
13.3.1 Agilent Technologies Company Details
13.3.2 Agilent Technologies Business Overview and Its Total Revenue
13.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
13.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.3.5 Agilent Technologies Recent Development
13.4 Astellas Pharmaceuticals
13.4.1 Astellas Pharmaceuticals Company Details
13.4.2 Astellas Pharmaceuticals Business Overview and Its Total Revenue
13.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
13.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.4.5 Astellas Pharmaceuticals Recent Development
13.5 BAYER AG
13.5.1 BAYER AG Company Details
13.5.2 BAYER AG Business Overview and Its Total Revenue
13.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
13.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.5.5 BAYER AG Recent Development
13.6 Bio Vision
13.6.1 Bio Vision Company Details
13.6.2 Bio Vision Business Overview and Its Total Revenue
13.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
13.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.6.5 Bio Vision Recent Development
13.7 Celgene Corp.
13.7.1 Celgene Corp. Company Details
13.7.2 Celgene Corp. Business Overview and Its Total Revenue
13.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
13.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.7.5 Celgene Corp. Recent Development
13.8 Emd Millipore
13.8.1 Emd Millipore Company Details
13.8.2 Emd Millipore Business Overview and Its Total Revenue
13.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
13.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.8.5 Emd Millipore Recent Development
13.9 Epigenomics AG
13.9.1 Epigenomics AG Company Details
13.9.2 Epigenomics AG Business Overview and Its Total Revenue
13.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
13.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.9.5 Epigenomics AG Recent Development
13.10 Epigentex
13.10.1 Epigentex Company Details
13.10.2 Epigentex Business Overview and Its Total Revenue
13.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
13.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
13.10.5 Epigentex Recent Development
13.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
10.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
10.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview and Its Total Revenue
10.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
10.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
13.12 Gilead Sciences
10.12.1 Gilead Sciences Company Details
10.12.2 Gilead Sciences Business Overview and Its Total Revenue
10.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
10.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.12.5 Gilead Sciences Recent Development
13.13 Glaxosmithkline
10.13.1 Glaxosmithkline Company Details
10.13.2 Glaxosmithkline Business Overview and Its Total Revenue
10.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
10.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.13.5 Glaxosmithkline Recent Development
13.14 Illumina Inc.
10.14.1 Illumina Inc. Company Details
10.14.2 Illumina Inc. Business Overview and Its Total Revenue
10.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
10.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.14.5 Illumina Inc. Recent Development
13.15 Johnson & Johnson
10.15.1 Johnson & Johnson Company Details
10.15.2 Johnson & Johnson Business Overview and Its Total Revenue
10.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
10.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.15.5 Johnson & Johnson Recent Development
13.16 Karus Therapeutics Limited
10.16.1 Karus Therapeutics Limited Company Details
10.16.2 Karus Therapeutics Limited Business Overview and Its Total Revenue
10.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
10.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.16.5 Karus Therapeutics Limited Recent Development
13.17 Laboratory Corp. Of America Holdings
10.17.1 Laboratory Corp. Of America Holdings Company Details
10.17.2 Laboratory Corp. Of America Holdings Business Overview and Its Total Revenue
10.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
10.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.17.5 Laboratory Corp. Of America Holdings Recent Development
13.18 LES Laboratoires Servier
10.18.1 LES Laboratoires Servier Company Details
10.18.2 LES Laboratoires Servier Business Overview and Its Total Revenue
10.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
10.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.18.5 LES Laboratoires Servier Recent Development
13.19 Merck
10.19.1 Merck Company Details
10.19.2 Merck Business Overview and Its Total Revenue
10.19.3 Merck Personalized Medicine and Epigenomics Introduction
10.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.19.5 Merck Recent Development
13.20 Naturewise Biotech & Medicals Corp.
10.20.1 Naturewise Biotech & Medicals Corp. Company Details
10.20.2 Naturewise Biotech & Medicals Corp. Business Overview and Its Total Revenue
10.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
10.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.20.5 Naturewise Biotech & Medicals Corp. Recent Development
13.21 Novartis Pharma AG
10.21.1 Novartis Pharma AG Company Details
10.21.2 Novartis Pharma AG Business Overview and Its Total Revenue
10.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
10.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.21.5 Novartis Pharma AG Recent Development
13.22 Oncolys Biopharma Inc.
10.22.1 Oncolys Biopharma Inc. Company Details
10.22.2 Oncolys Biopharma Inc. Business Overview and Its Total Revenue
10.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
10.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.22.5 Oncolys Biopharma Inc. Recent Development
13.23 Orchid Chemicals & Pharmaceuticals Limited
10.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
10.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview and Its Total Revenue
10.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
10.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
13.24 Progen Pharmaceuticals Limited
10.24.1 Progen Pharmaceuticals Limited Company Details
10.24.2 Progen Pharmaceuticals Limited Business Overview and Its Total Revenue
10.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
10.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.24.5 Progen Pharmaceuticals Limited Recent Development
13.25 Quest Diagnostics
10.25.1 Quest Diagnostics Company Details
10.25.2 Quest Diagnostics Business Overview and Its Total Revenue
10.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
10.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.25.5 Quest Diagnostics Recent Development
13.26 Roche Holding AG
10.26.1 Roche Holding AG Company Details
10.26.2 Roche Holding AG Business Overview and Its Total Revenue
10.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
10.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.26.5 Roche Holding AG Recent Development
13.27 Rubicon Genomics
10.27.1 Rubicon Genomics Company Details
10.27.2 Rubicon Genomics Business Overview and Its Total Revenue
10.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
10.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.27.5 Rubicon Genomics Recent Development
13.28 Takeda Pharmaceutical Company Limited
10.28.1 Takeda Pharmaceutical Company Limited Company Details
10.28.2 Takeda Pharmaceutical Company Limited Business Overview and Its Total Revenue
10.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
10.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
10.28.5 Takeda Pharmaceutical Company Limited Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Personalized Medicine and Epigenomics Key Market Segments
Table 2. Key Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
Table 3. Ranking of Global Top Personalized Medicine and Epigenomics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Reagents
Table 6. Key Players of Kits
Table 7. Key Players of Instruments
Table 8. Key Players of Enzymes
Table 9. Key Players of Services
Table 10. COVID-19 Impact Global Market: (Four Personalized Medicine and Epigenomics Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Personalized Medicine and Epigenomics Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Personalized Medicine and Epigenomics Players to Combat Covid-19 Impact
Table 15. Global Personalized Medicine and Epigenomics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Personalized Medicine and Epigenomics Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Personalized Medicine and Epigenomics Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Personalized Medicine and Epigenomics Market Share by Regions (2015-2020)
Table 19. Global Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Personalized Medicine and Epigenomics Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Personalized Medicine and Epigenomics Market Growth Strategy
Table 25. Main Points Interviewed from Key Personalized Medicine and Epigenomics Players
Table 26. Global Personalized Medicine and Epigenomics Revenue by Players (2015-2020) (Million US$)
Table 27. Global Personalized Medicine and Epigenomics Market Share by Players (2015-2020)
Table 28. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2019)
Table 29. Global Personalized Medicine and Epigenomics by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Personalized Medicine and Epigenomics Product Solution and Service
Table 32. Date of Enter into Personalized Medicine and Epigenomics Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 35. Global Personalized Medicine and Epigenomics Market Size Share by Type (2015-2020)
Table 36. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2021-2026)
Table 37. Global Personalized Medicine and Epigenomics Market Size Share by Application (2015-2020)
Table 38. Global Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 39. Global Personalized Medicine and Epigenomics Market Size Share by Application (2021-2026)
Table 40. North America Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 42. North America Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 43. North America Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 44. North America Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 45. North America Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 46. Europe Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 48. Europe Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 50. Europe Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 52. China Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 53. China Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 54. China Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 55. China Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 56. China Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 57. China Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 58. Japan Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 60. Japan Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 62. Japan Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 66. Southeast Asia Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 68. Southeast Asia Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 70. India Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 71. India Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 72. India Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 73. India Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 74. India Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 75. India Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 78. Central & South America Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 80. Central & South America Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 82. Abbott Laboratories Company Details
Table 83. Abbott Laboratories Business Overview
Table 84. Abbott Laboratories Product
Table 85. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 86. Abbott Laboratories Recent Development
Table 87. Affymetrix Company Details
Table 88. Affymetrix Business Overview
Table 89. Affymetrix Product
Table 90. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 91. Affymetrix Recent Development
Table 92. Agilent Technologies Company Details
Table 93. Agilent Technologies Business Overview
Table 94. Agilent Technologies Product
Table 95. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 96. Agilent Technologies Recent Development
Table 97. Astellas Pharmaceuticals Company Details
Table 98. Astellas Pharmaceuticals Business Overview
Table 99. Astellas Pharmaceuticals Product
Table 100. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 101. Astellas Pharmaceuticals Recent Development
Table 102. BAYER AG Company Details
Table 103. BAYER AG Business Overview
Table 104. BAYER AG Product
Table 105. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 106. BAYER AG Recent Development
Table 107. Bio Vision Company Details
Table 108. Bio Vision Business Overview
Table 109. Bio Vision Product
Table 110. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 111. Bio Vision Recent Development
Table 112. Celgene Corp. Company Details
Table 113. Celgene Corp. Business Overview
Table 114. Celgene Corp. Product
Table 115. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 116. Celgene Corp. Recent Development
Table 117. Emd Millipore Business Overview
Table 118. Emd Millipore Product
Table 119. Emd Millipore Company Details
Table 120. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 121. Emd Millipore Recent Development
Table 122. Epigenomics AG Company Details
Table 123. Epigenomics AG Business Overview
Table 124. Epigenomics AG Product
Table 125. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 126. Epigenomics AG Recent Development
Table 127. Epigentex Company Details
Table 128. Epigentex Business Overview
Table 129. Epigentex Product
Table 130. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 131. Epigentex Recent Development
Table 132. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
Table 133. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
Table 134. Envivo Pharmaceuticals (Forum Pharmaceutricals) Product
Table 135. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 136. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
Table 137. Gilead Sciences Company Details
Table 138. Gilead Sciences Business Overview
Table 139. Gilead Sciences Product
Table 140. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 141. Gilead Sciences Recent Development
Table 142. Glaxosmithkline Company Details
Table 143. Glaxosmithkline Business Overview
Table 144. Glaxosmithkline Product
Table 145. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 146. Glaxosmithkline Recent Development
Table 147. Illumina Inc. Company Details
Table 148. Illumina Inc. Business Overview
Table 149. Illumina Inc. Product
Table 150. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 151. Illumina Inc. Recent Development
Table 152. Johnson & Johnson Company Details
Table 153. Johnson & Johnson Business Overview
Table 154. Johnson & Johnson Product
Table 155. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 156. Johnson & Johnson Recent Development
Table 157. Karus Therapeutics Limited Company Details
Table 158. Karus Therapeutics Limited Business Overview
Table 159. Karus Therapeutics Limited Product
Table 160. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 161. Karus Therapeutics Limited Recent Development
Table 162. Laboratory Corp. Of America Holdings Company Details
Table 163. Laboratory Corp. Of America Holdings Business Overview
Table 164. Laboratory Corp. Of America Holdings Product
Table 165. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 166. Laboratory Corp. Of America Holdings Recent Development
Table 167. LES Laboratoires Servier Company Details
Table 168. LES Laboratoires Servier Business Overview
Table 169. LES Laboratoires Servier Product
Table 170. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 171. LES Laboratoires Servier Recent Development
Table 172. Merck Company Details
Table 173. Merck Business Overview
Table 174. Merck Product
Table 175. Merck Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 176. Merck Recent Development
Table 177. Naturewise Biotech & Medicals Corp. Company Details
Table 178. Naturewise Biotech & Medicals Corp. Business Overview
Table 179. Naturewise Biotech & Medicals Corp. Product
Table 180. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 181. Naturewise Biotech & Medicals Corp. Recent Development
Table 182. Novartis Pharma AG Company Details
Table 183. Novartis Pharma AG Business Overview
Table 184. Novartis Pharma AG Product
Table 185. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 186. Novartis Pharma AG Recent Development
Table 187. Oncolys Biopharma Inc. Company Details
Table 188. Oncolys Biopharma Inc. Business Overview
Table 189. Oncolys Biopharma Inc. Product
Table 190. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 191. Oncolys Biopharma Inc. Recent Development
Table 192. Orchid Chemicals & Pharmaceuticals Limited Company Details
Table 193. Orchid Chemicals & Pharmaceuticals Limited Business Overview
Table 194. Orchid Chemicals & Pharmaceuticals Limited Product
Table 195. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 196. Orchid Chemicals & Pharmaceuticals Limited Recent Development
Table 197. Progen Pharmaceuticals Limited Company Details
Table 198. Progen Pharmaceuticals Limited Business Overview
Table 199. Progen Pharmaceuticals Limited Product
Table 200. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 201. Progen Pharmaceuticals Limited Recent Development
Table 202. Quest Diagnostics Company Details
Table 203. Quest Diagnostics Business Overview
Table 204. Quest Diagnostics Product
Table 205. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 206. Quest Diagnostics Recent Development
Table 207. Roche Holding AG Company Details
Table 208. Roche Holding AG Business Overview
Table 209. Roche Holding AG Product
Table 210. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 211. Roche Holding AG Recent Development
Table 212. Rubicon Genomics Company Details
Table 213. Rubicon Genomics Business Overview
Table 214. Rubicon Genomics Product
Table 215. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 216. Rubicon Genomics Recent Development
Table 217. Takeda Pharmaceutical Company Limited Company Details
Table 218. Takeda Pharmaceutical Company Limited Business Overview
Table 219. Takeda Pharmaceutical Company Limited Product
Table 220. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 221. Takeda Pharmaceutical Company Limited Recent Development
Table 222. Research Programs/Design for This Report
Table 223. Key Data Information from Secondary Sources
Table 224. Key Data Information from Primary Sources
Table 1. Personalized Medicine and Epigenomics Key Market Segments
Table 2. Key Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
Table 3. Ranking of Global Top Personalized Medicine and Epigenomics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Reagents
Table 6. Key Players of Kits
Table 7. Key Players of Instruments
Table 8. Key Players of Enzymes
Table 9. Key Players of Services
Table 10. COVID-19 Impact Global Market: (Four Personalized Medicine and Epigenomics Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Personalized Medicine and Epigenomics Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Personalized Medicine and Epigenomics Players to Combat Covid-19 Impact
Table 15. Global Personalized Medicine and Epigenomics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Personalized Medicine and Epigenomics Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Personalized Medicine and Epigenomics Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Personalized Medicine and Epigenomics Market Share by Regions (2015-2020)
Table 19. Global Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Personalized Medicine and Epigenomics Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Personalized Medicine and Epigenomics Market Growth Strategy
Table 25. Main Points Interviewed from Key Personalized Medicine and Epigenomics Players
Table 26. Global Personalized Medicine and Epigenomics Revenue by Players (2015-2020) (Million US$)
Table 27. Global Personalized Medicine and Epigenomics Market Share by Players (2015-2020)
Table 28. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2019)
Table 29. Global Personalized Medicine and Epigenomics by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Personalized Medicine and Epigenomics Product Solution and Service
Table 32. Date of Enter into Personalized Medicine and Epigenomics Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 35. Global Personalized Medicine and Epigenomics Market Size Share by Type (2015-2020)
Table 36. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2021-2026)
Table 37. Global Personalized Medicine and Epigenomics Market Size Share by Application (2015-2020)
Table 38. Global Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 39. Global Personalized Medicine and Epigenomics Market Size Share by Application (2021-2026)
Table 40. North America Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 42. North America Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 43. North America Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 44. North America Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 45. North America Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 46. Europe Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 48. Europe Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 50. Europe Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 52. China Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 53. China Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 54. China Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 55. China Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 56. China Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 57. China Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 58. Japan Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 60. Japan Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 62. Japan Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 66. Southeast Asia Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 68. Southeast Asia Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 70. India Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 71. India Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 72. India Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 73. India Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 74. India Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 75. India Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Personalized Medicine and Epigenomics Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Personalized Medicine and Epigenomics Market Share (2019-2020)
Table 78. Central & South America Personalized Medicine and Epigenomics Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Personalized Medicine and Epigenomics Market Share by Type (2015-2020)
Table 80. Central & South America Personalized Medicine and Epigenomics Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Personalized Medicine and Epigenomics Market Share by Application (2015-2020)
Table 82. Abbott Laboratories Company Details
Table 83. Abbott Laboratories Business Overview
Table 84. Abbott Laboratories Product
Table 85. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 86. Abbott Laboratories Recent Development
Table 87. Affymetrix Company Details
Table 88. Affymetrix Business Overview
Table 89. Affymetrix Product
Table 90. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 91. Affymetrix Recent Development
Table 92. Agilent Technologies Company Details
Table 93. Agilent Technologies Business Overview
Table 94. Agilent Technologies Product
Table 95. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 96. Agilent Technologies Recent Development
Table 97. Astellas Pharmaceuticals Company Details
Table 98. Astellas Pharmaceuticals Business Overview
Table 99. Astellas Pharmaceuticals Product
Table 100. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 101. Astellas Pharmaceuticals Recent Development
Table 102. BAYER AG Company Details
Table 103. BAYER AG Business Overview
Table 104. BAYER AG Product
Table 105. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 106. BAYER AG Recent Development
Table 107. Bio Vision Company Details
Table 108. Bio Vision Business Overview
Table 109. Bio Vision Product
Table 110. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 111. Bio Vision Recent Development
Table 112. Celgene Corp. Company Details
Table 113. Celgene Corp. Business Overview
Table 114. Celgene Corp. Product
Table 115. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 116. Celgene Corp. Recent Development
Table 117. Emd Millipore Business Overview
Table 118. Emd Millipore Product
Table 119. Emd Millipore Company Details
Table 120. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 121. Emd Millipore Recent Development
Table 122. Epigenomics AG Company Details
Table 123. Epigenomics AG Business Overview
Table 124. Epigenomics AG Product
Table 125. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 126. Epigenomics AG Recent Development
Table 127. Epigentex Company Details
Table 128. Epigentex Business Overview
Table 129. Epigentex Product
Table 130. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 131. Epigentex Recent Development
Table 132. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
Table 133. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
Table 134. Envivo Pharmaceuticals (Forum Pharmaceutricals) Product
Table 135. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 136. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
Table 137. Gilead Sciences Company Details
Table 138. Gilead Sciences Business Overview
Table 139. Gilead Sciences Product
Table 140. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 141. Gilead Sciences Recent Development
Table 142. Glaxosmithkline Company Details
Table 143. Glaxosmithkline Business Overview
Table 144. Glaxosmithkline Product
Table 145. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 146. Glaxosmithkline Recent Development
Table 147. Illumina Inc. Company Details
Table 148. Illumina Inc. Business Overview
Table 149. Illumina Inc. Product
Table 150. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 151. Illumina Inc. Recent Development
Table 152. Johnson & Johnson Company Details
Table 153. Johnson & Johnson Business Overview
Table 154. Johnson & Johnson Product
Table 155. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 156. Johnson & Johnson Recent Development
Table 157. Karus Therapeutics Limited Company Details
Table 158. Karus Therapeutics Limited Business Overview
Table 159. Karus Therapeutics Limited Product
Table 160. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 161. Karus Therapeutics Limited Recent Development
Table 162. Laboratory Corp. Of America Holdings Company Details
Table 163. Laboratory Corp. Of America Holdings Business Overview
Table 164. Laboratory Corp. Of America Holdings Product
Table 165. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 166. Laboratory Corp. Of America Holdings Recent Development
Table 167. LES Laboratoires Servier Company Details
Table 168. LES Laboratoires Servier Business Overview
Table 169. LES Laboratoires Servier Product
Table 170. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 171. LES Laboratoires Servier Recent Development
Table 172. Merck Company Details
Table 173. Merck Business Overview
Table 174. Merck Product
Table 175. Merck Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 176. Merck Recent Development
Table 177. Naturewise Biotech & Medicals Corp. Company Details
Table 178. Naturewise Biotech & Medicals Corp. Business Overview
Table 179. Naturewise Biotech & Medicals Corp. Product
Table 180. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 181. Naturewise Biotech & Medicals Corp. Recent Development
Table 182. Novartis Pharma AG Company Details
Table 183. Novartis Pharma AG Business Overview
Table 184. Novartis Pharma AG Product
Table 185. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 186. Novartis Pharma AG Recent Development
Table 187. Oncolys Biopharma Inc. Company Details
Table 188. Oncolys Biopharma Inc. Business Overview
Table 189. Oncolys Biopharma Inc. Product
Table 190. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 191. Oncolys Biopharma Inc. Recent Development
Table 192. Orchid Chemicals & Pharmaceuticals Limited Company Details
Table 193. Orchid Chemicals & Pharmaceuticals Limited Business Overview
Table 194. Orchid Chemicals & Pharmaceuticals Limited Product
Table 195. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 196. Orchid Chemicals & Pharmaceuticals Limited Recent Development
Table 197. Progen Pharmaceuticals Limited Company Details
Table 198. Progen Pharmaceuticals Limited Business Overview
Table 199. Progen Pharmaceuticals Limited Product
Table 200. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 201. Progen Pharmaceuticals Limited Recent Development
Table 202. Quest Diagnostics Company Details
Table 203. Quest Diagnostics Business Overview
Table 204. Quest Diagnostics Product
Table 205. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 206. Quest Diagnostics Recent Development
Table 207. Roche Holding AG Company Details
Table 208. Roche Holding AG Business Overview
Table 209. Roche Holding AG Product
Table 210. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 211. Roche Holding AG Recent Development
Table 212. Rubicon Genomics Company Details
Table 213. Rubicon Genomics Business Overview
Table 214. Rubicon Genomics Product
Table 215. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 216. Rubicon Genomics Recent Development
Table 217. Takeda Pharmaceutical Company Limited Company Details
Table 218. Takeda Pharmaceutical Company Limited Business Overview
Table 219. Takeda Pharmaceutical Company Limited Product
Table 220. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020) (Million US$)
Table 221. Takeda Pharmaceutical Company Limited Recent Development
Table 222. Research Programs/Design for This Report
Table 223. Key Data Information from Secondary Sources
Table 224. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Personalized Medicine and Epigenomics Market Share by Type: 2020 VS 2026
Figure 2. Reagents Features
Figure 3. Kits Features
Figure 4. Instruments Features
Figure 5. Enzymes Features
Figure 6. Services Features
Figure 7. Global Personalized Medicine and Epigenomics Market Share by Application: 2020 VS 2026
Figure 8. Oncology Case Studies
Figure 9. Non-Oncology Case Studies
Figure 10. Cancer Drug Technology Case Studies
Figure 11. Personalized Medicine and Epigenomics Report Years Considered
Figure 12. Global Personalized Medicine and Epigenomics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Personalized Medicine and Epigenomics Market Share by Regions: 2020 VS 2026
Figure 14. Global Personalized Medicine and Epigenomics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Personalized Medicine and Epigenomics Market Share by Players in 2019
Figure 17. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2019
Figure 19. North America Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 28. Affymetrix Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 30. Agilent Technologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 32. Astellas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 34. BAYER AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 36. Bio Vision Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 38. Celgene Corp. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 40. Emd Millipore Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 42. Epigenomics AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 44. Epigentex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 46. Envivo Pharmaceuticals (Forum Pharmaceutricals) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 48. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 50. Glaxosmithkline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 52. Illumina Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 54. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 56. Karus Therapeutics Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 58. Laboratory Corp. Of America Holdings Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 60. LES Laboratoires Servier Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 62. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 64. Naturewise Biotech & Medicals Corp. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Figure 1. Global Personalized Medicine and Epigenomics Market Share by Type: 2020 VS 2026
Figure 2. Reagents Features
Figure 3. Kits Features
Figure 4. Instruments Features
Figure 5. Enzymes Features
Figure 6. Services Features
Figure 7. Global Personalized Medicine and Epigenomics Market Share by Application: 2020 VS 2026
Figure 8. Oncology Case Studies
Figure 9. Non-Oncology Case Studies
Figure 10. Cancer Drug Technology Case Studies
Figure 11. Personalized Medicine and Epigenomics Report Years Considered
Figure 12. Global Personalized Medicine and Epigenomics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Personalized Medicine and Epigenomics Market Share by Regions: 2020 VS 2026
Figure 14. Global Personalized Medicine and Epigenomics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Personalized Medicine and Epigenomics Market Share by Players in 2019
Figure 17. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2019
Figure 19. North America Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Personalized Medicine and Epigenomics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 28. Affymetrix Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 30. Agilent Technologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 32. Astellas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 34. BAYER AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 36. Bio Vision Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 38. Celgene Corp. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 40. Emd Millipore Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 42. Epigenomics AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 44. Epigentex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 46. Envivo Pharmaceuticals (Forum Pharmaceutricals) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 48. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 50. Glaxosmithkline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 52. Illumina Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 54. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 56. Karus Therapeutics Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 58. Laboratory Corp. Of America Holdings Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 60. LES Laboratoires Servier Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 62. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 64. Naturewise Biotech & Medicals Corp. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2015-2020)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed